Related to Merck Teams with Adcock Ingram to Market OTC and Rx Products in South Africa

• Metabasis Chooses Single $6M Fee over $54M in Milestones from Merck & Co.
  
• Astellas to Commercialize NeurogesX’ Qutenza in Europe
  
• Merck and DNDi Team Up to Fight Neglected Tropical Diseases
  
• Merck & Co. Licenses Portola Phase II Stroke Therapy for $50M Up Front
  
• Addex Gets $500K from Merck & Co. for Reaching Preclinical Milestone
  
• Merck Pays Depomed $10M for Patents to Expand Use of Antidiabetic
  
• Covance Takes Over Merck & Co.’s Gene-Expression Lab and Gains $145M Contract
  
• Wellcome Trust and Merck Set Up JV to Focus on Vaccines for Developing Nations
  
• Merck & Co. to Market CSL’s Seasonal Flu Vaccine in the U.S.
  
• Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis
  
• Good and Bad News at Idera
  
• Merck & Co. Extends Research Arrangement with Addex for One More Year
  
• Hikma Negotiates Distribution Deal for Astellas’ Immunosuppressant in MENA Region
  
• Hospira Pays ChemGenex Roughly $16.25M Up Front for CML Therapy
  
• Galapagos Earns Just Over $5M from Merck & Co. for Achieving Milestones in Metabolic and Inflammatory Disease Deals
  
• Merck & Co. Taps Envoy for Target Discovery in Diabetes and Obesity
  
• Merck & Co. Passes Late-Stage Onychomycosis Therapy Back to Anacor
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• BG Medicine Forges Pact with Merck & Co. to Develop a Molecular Diagnostic for Lipid Disorders
  
• Lilly, Merck & Co., and Pfizer Establish Asian Cancer Research Group Focused on Lung and Gastric Cancers